EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Onset of vitiligo during bimekizumab treatment for psoriasis

Elodie Potereau, Yannick Le Corre, Elisabeth Polard, Marie Briet, Marina Babin

Therapies · 2026-09

DOI: 10.1016/j.therap.2026.09.044 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapies, 2026-09. Verfasst von Elodie Potereau und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology-Toxicology and Pharmacovigilance, University Hospital of Angers, 49100 Angers, France. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Psoriasis is an inflammatory skin disorder characterized by epithelial hyperplasia and infiltration of inflammatory cells. Several immunological therapies have been developed for its treatment, including IL-17 inhibitors such as secukinumab, ixekizumab and bimekizumab. The safety profile of IL-17 inhibitors includes infectious diseases, gastrointestinal disorders, headaches, and cutaneous conditions such as eczema. Here, we report the first case of vitiligo, a depigmenting skin disorder characterized by the selective loss of melanocytes, occurring during treatment with bimekizumab. This case involved a 42-year-old man who achieved complete skin clearance of psoriasis plaques under bimekizumab therapy. After 11 months of treatment, he developed vitiligo patches on his face. These lesions resolved following discontinuation of bimekizumab, minipulse therapy and ruxolitinib cream application. Vitiligo occurrence has been previously observed with other IL-17 inhibitors, including secukinumab and ixekizumab (11 other cases). Although IL-17 is believed to play a role in the pathophysiology of vitiligo, its exact mechanism remains unclear. Paradoxal vitiligo may represent a class effect of IL-17 inhibitors, particularly in patients with psoriasis. This potential adverse effect should be considered, especially in patients with a personal or family history of vitiligo or other depigmentation disorders. Interestingly, stability or even repigmentation has been observed in patients who continued anti-IL-17 therapy, regardless of whether they received symptomatic treatment. Given the efficacy of anti-IL17 inhibitors in psoriasis, the risk-benefit balance should be carefully discussed in this context.

Schlagwörter

Stichwörter der Autor:innen

Adverse effectsBimekizumabInterleukin-17 inhibitorsPsoriasisVitiligo

Autor:innen und Institutionen

  • Department of Pharmacology-Toxicology and Pharmacovigilance, University Hospital of Angers, 49100 Angers, France.
  • Department of Dermatology, University Hospital of Angers, 49100 Angers, France.
  • Department of Medical Pharmacology, Centre of Pharmacovigilance and Pharmacoepidemiology, University Hospital of Rennes, Rennes, France.
  • Department of Pharmacology-Toxicology and Pharmacovigilance, University Hospital of Angers, 49100 Angers, France; Angers University, 49035 Angers, France; Research Institute MitoVasc, UMR CNRS 6214 Inserm 1083, 49100 An…

Zitieren

APA

Potereau, E., Le Corre, Y., Polard, E., Briet, M., & Babin, M. (2026). Onset of vitiligo during bimekizumab treatment for psoriasis. Therapies. https://doi.org/10.1016/j.therap.2026.09.044

Vancouver

Potereau E, Le Corre Y, Polard E, Briet M, Babin M. Onset of vitiligo during bimekizumab treatment for psoriasis. Therapies. 2026. doi:10.1016/j.therap.2026.09.044

BibTeX
@article{Potereau2026,
  author = {Potereau, Elodie and Le Corre, Yannick and Polard, Elisabeth and Briet, Marie and Babin, Marina},
  title = {Onset of vitiligo during bimekizumab treatment for psoriasis},
  journal = {Therapies},
  year = {2026},
  doi = {10.1016/j.therap.2026.09.044}
}
Kostenlos starten →